デブリゾクインヒドロキシラーゼ遺伝子ポリモルフィズムとパーキンソン病の感受性
C A Smith1, A C Gough, P N Leigh
1Imperial Cancer Research Fund Molecular Pharmacology Group, George Square, Edinburgh, UK.
Lancet (London, England)
|June 6, 1992
まとめ
サイトクロームP450CYP2D6遺伝子の遺伝的変異は,パーキンソン病のリスクを高めます. この遺伝子の代謝が悪い人は2.54倍のリスクを示しており,環境要因とパーキンソン病の病原性との関連を示唆しています.
科学分野:
- 神経科学は神経科学である.
- 遺伝学 遺伝学とは
- 薬理学 薬理学とは
背景:
- パーキンソン病の病原性には,遺伝的および環境的要因が関係しています.
- サイトクロームP450モノオキシゲナーゼ (CYP450s) は,環境化合物を解毒する.
- CYP450発現の変動は,環境関連疾患に対する感受性に影響を与える可能性があります.
研究 の 目的:
- CYP2D6遺伝子変異とパーキンソン病のリスクとの関連を調べる.
- パーキンソン病の感受性におけるCYP2D6代謝フェノタイプの役割を調査する.
主な方法:
- パーキンソン病患者および対照群におけるCYP2D6遺伝子の遺伝子型およびフェノタイプ化.
- アレル周波数と代謝現象型を比較したケース・コントロール研究.
主要な成果:
- この研究では,229人のパーキンソン病患者と720人の対照群を対象とした.
- CYP2D6-デブリゾクインヒドロキシラゼ遺伝子のメタボライザーのフェノタイプが悪い個人は,パーキンソン病のリスクが2.54倍増加しました (95%CI 1.51-4.28).
結論:
- CYP2D6の遺伝子型とフェノタイプは,パーキンソン病のリスクが高い個人を特定するのに役立ちます.
- この発見は,環境要因と代謝経路が,パーキンソン病の発症における潜在的な役割を示唆しています.
関連する概念動画
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...